Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) have been established as important diagnostic and guidance tools for percutaneous coronary intervention (PCI) procedures1. Sequential use of the two modalities might overcome the inherent limitations of each technology; however, the potential risks of complications and cost are hard to ignore. Hybrid IVUS-OCT systems can overcome the limitations associated with each technology and integrate the advantages of both modalities. In 2018, a hybrid IVUS-OCT system for clinical application was reported for the first time2. Recently, a novel hybrid imaging system was approved for clinical use (PANOVISON; Panovision Co., Ltd), allowing synchronous acquisition of the two imaging modalities and an immediate, coregistered image review. We conducted this first-in-human study to test each modality of the hybrid imaging system, representing this novel device’s first large-scale human application.
The study was a prospective, multicentre, randomised, open-label, self-controlled, non-inferiority trial. The protocol was approved by the institutional review boards and ethics committees in all participating centres. All patients provided written informed consent. Specific inclusion and exclusion criteria are described at ClinicalTrials.gov: NCT05596279. We used a web-based randomisation service...
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com